These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
476 related articles for article (PubMed ID: 19846026)
21. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Yuan Y; Iloeje U; Li H; Hay J; Yao GB Value Health; 2008 Mar; 11 Suppl 1():S11-22. PubMed ID: 18387054 [TBL] [Abstract][Full Text] [Related]
22. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B. Gish RG; Chang TT; Lai CL; de Man R; Gadano A; Poordad F; Yang J; Brett-Smith H; Tamez R J Viral Hepat; 2010 Jan; 17(1):16-22. PubMed ID: 19622117 [TBL] [Abstract][Full Text] [Related]
23. Febuxostat for the treatment of hyperuricaemia in people with gout: a single technology appraisal. Stevenson M; Pandor A Health Technol Assess; 2009 Oct; 13 Suppl 3():37-42. PubMed ID: 19846027 [TBL] [Abstract][Full Text] [Related]
24. The clinical effectiveness and cost-effectiveness of rituximab for the first-line treatment of chronic lymphocytic leukaemia: an evidence review of the submission from Roche. Main C; Pitt M; Moxham T; Stein K Health Technol Assess; 2010 Oct; 14(Suppl. 2):27-32. PubMed ID: 21047488 [TBL] [Abstract][Full Text] [Related]
25. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal. Ward S; Pilgrim H; Hind D Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207 [TBL] [Abstract][Full Text] [Related]
26. Treatment of chronic hepatitis B virus infection - Dutch national guidelines. Buster EH; van Erpecum KJ; Schalm SW; Zaaijer HL; Brouwer JT; Gelderblom HC; de Knegt RJ; Minke Bakker C; Reesink HW; Janssen HL; Neth J Med; 2008; 66(7):292-306. PubMed ID: 18663260 [TBL] [Abstract][Full Text] [Related]
27. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D; N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137 [TBL] [Abstract][Full Text] [Related]
28. A review of entecavir in the treatment of chronic hepatitis B infection. Rivkin A Curr Med Res Opin; 2005 Nov; 21(11):1845-56. PubMed ID: 16307706 [TBL] [Abstract][Full Text] [Related]
29. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. Lai CL; Shouval D; Lok AS; Chang TT; Cheinquer H; Goodman Z; DeHertogh D; Wilber R; Zink RC; Cross A; Colonno R; Fernandes L; N Engl J Med; 2006 Mar; 354(10):1011-20. PubMed ID: 16525138 [TBL] [Abstract][Full Text] [Related]
30. [Cost-effectiveness analysis of entecavir versus lamivudine in patients with chronic hepatitis B]. Calcagno JI; Augustovski F; Gadano A; Souto A; Yuan Y Acta Gastroenterol Latinoam; 2008 Dec; 38(4):260-73. PubMed ID: 19157381 [TBL] [Abstract][Full Text] [Related]
31. Cross-study analysis of the relative efficacies of oral antiviral therapies for chronic hepatitis B infection in nucleoside-naive patients. Dienstag JL; Wei LJ; Xu D; Kreter B Clin Drug Investig; 2007; 27(1):35-49. PubMed ID: 17177578 [TBL] [Abstract][Full Text] [Related]
32. Cost effectiveness of entecavir versus lamivudine with adefovir salvage in HBeAg-positive chronic hepatitis B. Veenstra DL; Sullivan SD; Clarke L; Iloeje UH; Tafesse E; Di Bisceglie A; Kowdley KV; Gish RG Pharmacoeconomics; 2007; 25(11):963-77. PubMed ID: 17960954 [TBL] [Abstract][Full Text] [Related]
33. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Wu IC; Lai CL; Han SH; Han KH; Gordon SC; Chao YC; Tan CK; Sievert W; Tanwandee T; Xu D; Neo BL; Chang TT Hepatology; 2010 Apr; 51(4):1185-9. PubMed ID: 20044806 [TBL] [Abstract][Full Text] [Related]
34. Incorporated antivirals for chronic hepatitis B in Brazil: a cost-effectiveness analysis. Oliveira GL; Almeida AM; Silva AL; Brandão CM; Andrade EI; Cherchiglia ML; Acurcio Fde A Rev Saude Publica; 2013 Aug; 47(4):769-78; discussion 779. PubMed ID: 24346678 [TBL] [Abstract][Full Text] [Related]
35. Rituximab for the treatment of relapsed/refractory chronic lymphocytic leukaemia. Dretzke J; Barton P; Kaambwa B; Connock M; Uthman O; Bayliss S; Meads C Health Technol Assess; 2010 Oct; 14(Suppl. 2):19-26. PubMed ID: 21047487 [TBL] [Abstract][Full Text] [Related]
36. Entecavir: new drug. Chronic hepatitis B: a last resort. Prescrire Int; 2007 Oct; 16(91):183-5. PubMed ID: 17926822 [TBL] [Abstract][Full Text] [Related]
37. Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation. Jones J; Shepherd J; Baxter L; Gospodarevskaya E; Hartwell D; Harris P; Price A Health Technol Assess; 2009 Jul; 13(35):1-172, iii. PubMed ID: 19607759 [TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of entecavir versus lamivudine in the first-line treatment of Australian patients with chronic hepatitis B. Arnold E; Yuan Y; Iloeje U; Cook G Appl Health Econ Health Policy; 2008; 6(4):231-46. PubMed ID: 19382822 [TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of roadmap models in chronic hepatitis B using tenofovir as the rescue therapy. Lui YY; Tsoi KK; Wong VW; Kao JH; Hou JL; Teo EK; Mohamed R; Piratvisuth T; Han KH; Mihm U; Wong GL; Chan HL Antivir Ther; 2010; 15(2):145-55. PubMed ID: 20386069 [TBL] [Abstract][Full Text] [Related]
40. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B. Rivkin A Drugs Today (Barc); 2007 Apr; 43(4):201-20. PubMed ID: 17460784 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]